NCT02954874 2026-04-13
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
4 trialsNCT05812807 2026-04-07
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT03418961 2025-10-08
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
Phase 3 Recruiting
NCT00189631 2005-12-08
UFT/LV Maintenance Vs Observation in Metastatic Breast Cancer Responsive to Chemotherapy
Association Européenne de Recherche en Oncologie
Phase 3 Unknown